Among the potential molecular targets, cell cycle regulatory proteins, including cyclins and cyclin-dependent kinases (CDKs), have been under intense investigation because their functions are well regulated in normal cells but not in tumor cells. Flavopiridol, a synthetic flavone obtained from Dysoxylum benectiferum, a medicinal plant indigenous to India, is the first CDK inhibitor to enter clinical trials as anti-cancer agent. It has been shown to exert antitumor activity in preclinical studies and has undergone clinical trials as a single agent as well as in combination with chemotherapeutic agents. It has been shown to be effective in metastatic renal carcinoma; non-¬Hodgkin's lymphoma; breast, prostate, colon, ovarian and gastric carcinoma; it induces apoptosis, promotes differentiation, inhibits angiogenic process and modulates transcription events and signal transduction pathway. Presently, it is in advanced stage of clinical trials. Promising results have been seen in terms of its potential therapeutic efficacy in cancer therapy.
|Number of pages||2|
|Publication status||Published - Jun 1 2007|
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)